Valiant Laboratories IPO – Subscription Status, Allotment & Other Key Dates

Recently, Valiant Laboratories, a prominent Indian pharmaceutical ingredient manufacturer, made its foray into the world of Initial Public Offerings (IPOs). From September 27 to October 3, 2023, the IPO attracted a frenzy of investor interest, and the subscription rate reached a staggering 29.76 times the number of shares on offer by the final day.

Interestingly, Valiant Laboratories has experienced consistent revenue growth in recent years. The company’s IPO, which was open for subscription from September 27, was priced at a band of ₹133 to ₹140 per equity share for the public offering.

The distribution of shares in the IPO was divided as follows:

• Qualified Institutional Buyers (QIBs) – up to 50%
• Non-Institutional Investors (NIIs) – at least 15%
• Retail Investors – a minimum of 35%

Valiant Laboratories IPO Subscription Status

As the days progressed, the subscription status kept investors on the edge. Retail investors displayed remarkable enthusiasm on the fourth day, subscribing to their portion 16.06 times. Meanwhile, Non-Institutional Investors (NIIs) exhibited extraordinary interest by subscribing a whopping 73.64 times, and Qualified Institutional Buyers (QIBs) followed closely behind, oversubscribing their portion by 20.83 times.

Here is a brief overview of Valiant Laboratories IPO subscription status throughout its offering:

With such robust demand, it’s clear that Valiant Laboratories’ IPO has captured the market’s attention and investor confidence.

Valiant Laboratories IPO Allotment & Listing Date

For those eagerly awaiting their allotment, the schedule is as follows:

Basis for Allotment	October 5
Refunds	October 6
Credit of Shares in Demat a/c	October 6
Listing Date	October 9

The Valiant Laboratories IPO details are as follows:

Total issue size	Rs 152.46 Crores
Face Value	Rs 10 per share
Fresh issue size	10,890,000 shares
Price Band	Rs. 133 -140
Lot size	105 shares

How do you check Valiant Laboratories IPO allotment status?

You can check your allotment status online if you’ve applied for the Valiant Laboratories IPO. There are two methods to do so:

Option 1: Checking on the BSE Website:

Visit the BSE IPO allotment page: BSE IPO Allotment

• Select “Equity” under “Issue Type.”
• Choose “Valiant Laboratories Ltd” from the dropdown under “Issue Name.”
• Enter your Application Number or PAN.
• Complete the CAPTCHA verification.
• Click the “Search” button.

Option 2: Checking on Link Intime India Private Limited’s Website (IPO Registrar):

Visit the Link Intime IPO status page: Link Intime IPO Status.

• Select “Valiant Laboratories Ltd” from the dropdown (once the data is available).
• Choose one of the four options to access your allotment status: PAN, Application Number, DPID/Client ID, or Bank Account/IFSC.
• Enter the relevant details.
• Click the “Search” button.

When will the basis of allotment for Valiant Laboratories IPO be finalized?

The basis of allotment for Valiant Laboratories Ltd is set to be finalized on October 5, 2023. The company will initiate the refund process on October 6, 2023. You can expect their shares to be credited to their demat accounts on October 6, 2023.

It’s worth noting that the listing of Valiant Laboratories’ stock on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE) is scheduled for October 9, 2023.

Further, the stock is expected to list on Monday, October 9, 2023, and given the robust demand and the current grey market premium of +22, investors can anticipate an estimated listing price of ₹162 per share, representing a 15.71% premium over the IPO issue price of ₹140.

With a strong grey market premium and an estimated listing price, Valiant Laboratories IPO not only reflects the company’s potential but also showcases the enthusiasm of investors to be a part of its journey. As the stock is poised to hit the market on October 9, 2023, we can anticipate an exciting and rewarding chapter ahead for all of you.

*Disclaimer Note: The securities quoted, if any, are for illustration only and are not recommendatory. This article is for education purposes only and shall not be considered as recommendation or investment advice by Research & Ranking. We will not be liable for any losses that may occur. Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, membership of BASL, and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors.

FAQ